Glaukos Corporation (NYSE:GKOS)‘s stock had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies in a research report issued on Friday. They presently have a $38.00 price target on the medical instruments supplier’s stock. Piper Jaffray Companies’ price objective would suggest a potential upside of 12.29% from the stock’s current price.

A number of other brokerages also recently issued reports on GKOS. BidaskClub raised shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a report on Saturday, June 24th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $60.00 target price on shares of Glaukos Corporation in a research note on Thursday. Zacks Investment Research downgraded shares of Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Roth Capital lowered their target price on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Finally, BMO Capital Markets reaffirmed a “buy” rating and issued a $54.00 target price on shares of Glaukos Corporation in a research note on Friday, September 1st. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Glaukos Corporation currently has a consensus rating of “Buy” and an average price target of $49.86.

Shares of Glaukos Corporation (GKOS) traded down 6.06% during midday trading on Friday, hitting $31.79. 2,888,682 shares of the company traded hands. The stock’s market capitalization is $1.09 billion. The stock has a 50 day moving average of $39.49 and a 200-day moving average of $43.11. Glaukos Corporation has a 52 week low of $28.72 and a 52 week high of $52.49.

TRADEMARK VIOLATION NOTICE: “Piper Jaffray Companies Reaffirms Buy Rating for Glaukos Corporation (GKOS)” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/09/15/glaukos-corporation-gkos-given-new-38-00-price-target-at-piper-jaffray-companies.html.

In other Glaukos Corporation news, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc sold 325,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $37.93, for a total transaction of $12,327,250.00. The disclosure for this sale can be found here. Insiders sold 980,200 shares of company stock worth $37,900,263 over the last ninety days. 16.40% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC bought a new position in Glaukos Corporation during the second quarter valued at approximately $129,356,000. Capital World Investors grew its position in Glaukos Corporation by 17.1% during the second quarter. Capital World Investors now owns 2,740,000 shares of the medical instruments supplier’s stock valued at $113,628,000 after acquiring an additional 400,000 shares during the last quarter. William Blair Investment Management LLC grew its position in Glaukos Corporation by 4.9% during the second quarter. William Blair Investment Management LLC now owns 2,164,764 shares of the medical instruments supplier’s stock valued at $89,773,000 after acquiring an additional 100,320 shares during the last quarter. Janus Capital Management LLC grew its position in Glaukos Corporation by 88.5% during the first quarter. Janus Capital Management LLC now owns 1,765,069 shares of the medical instruments supplier’s stock valued at $90,545,000 after acquiring an additional 828,567 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in Glaukos Corporation by 3.4% during the second quarter. Vanguard Group Inc. now owns 1,668,345 shares of the medical instruments supplier’s stock valued at $69,187,000 after acquiring an additional 55,507 shares during the last quarter.

Glaukos Corporation Company Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Analyst Recommendations for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.